HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification

Impact · against what's priced in

HUTCHMED and AstraZeneca receive a positive catalyst from the NMPA's conditional approval of ORPATHYS for MET-amplified gastric cancer in China. The approval creates a new revenue stream targeting an estimated 18,000 patients annually and establishes a first-mover advantage in this specific oncology niche.

HCM+0.60

No priced-in read yet